东亚药业(605177) - 投资者关系活动记录表

Group 1: Company Strategy and Development - The company has a long-term development strategy centered on active pharmaceutical ingredients (APIs), focusing on strengthening its market competitiveness while increasing investment in generic and innovative drugs [2] - The company is expanding into material chemistry and pharmaceutical formulations, with ongoing projects funded by convertible bonds [2][4] Group 2: Financial Performance and Market Response - The company's net profit for the third quarter has declined year-on-year due to increased management and research expenses as the business scales up [3] - The company has consistently implemented dividends since its listing, emphasizing its commitment to investor returns despite stock price fluctuations influenced by macroeconomic factors [2] Group 3: Investor Relations and Communication - The company is actively managing investor relations, with regular updates and responses to investor inquiries through platforms like Shanghai Stock Exchange [3] - There are no current plans for mergers or acquisitions, and any future plans will be disclosed in accordance with regulations [3] Group 4: Project Updates and Future Outlook - The company is currently developing two convertible bond-funded projects, with new products in the development and approval stages [3][4] - The company has laid out projects in 14 disease areas, including gastrointestinal diseases and chronic kidney disease, focusing on both APIs and formulations [4]